ClinicalTrials.gg
CompletedNCT05143827Updated Oct 27, 2026

Glycemic Index of Pasta From Traditional and Current Wheat Varieties

An interventional study of Pasta manufactured with traditional wheat varieties (Senatore Cappelli, Korasan) and Pasta manufactured with current wheat varieties (Claudio) in Diabetes Type 2, sponsored by Azienda Ospedaliero-Universitaria Careggi. Completed at 1 site in Italy. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2026-10-27.

Sponsored by Azienda Ospedaliero-Universitaria Careggi · Not applicable, Interventional, and Other

How we know

Updated Oct 27, 2026Now CompletedPrimary completion moved+4 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
30
Allocation
Randomized
Ages
18 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 421 studies in Diabetes Mellitus, Type 2 with a site in Italy — 45 open to participants now, 61 under way, 12 of them phase 3. Diabetes Mellitus, Type 2 · Italy.

Enrollment
297th of 321
30 · median 320
Started
2021
with 17 others
No phase
71 of 421
14 open now
Registered
322nd of 421
by date

Among the 421 studies in Diabetes Mellitus, Type 2 with a site in Italy, this one is the 297th largest by enrollment of the 321 interventional ones that give a count, is one of 18 that started in 2021, is one of 71 with no phase, and was the 322nd registered.

Diabetes Mellitus, Type 2

10,403 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,413 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

45 of the 421 studies in Diabetes Mellitus, Type 2 with a site in Italy are open now. Recruiting first, the newest first:

40 more — sign in →

All 45 open studies →

A study can be open while its sites in Italy have not opened yet or have stopped. Only those recruiting at a site in Italy →

Who these studies take

Of the 882 Diabetes Mellitus, Type 2 studies recruiting now, 372 (42%) set no upper age limit and 384 (44%) stop at 75 or younger; 52 take children under 18; 202 take healthy volunteers.

This study: 18 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 421 studies in Diabetes Mellitus, Type 2 with a site in Italy, or all of them as a file.
02

Study summary

This randomized, cross-over study compares pasta produced with three different wheat varieties (Senatore Cappelli, Korasan, Claudio). Patients with type 2 diabetes with no pharmacological treatment will be randomized to three different sequences, and asked to eat a standard portion of pasta on three different occasions, four days apart. 3-hour post-prandial interstitial glucose profiles will be recorded using trans-cutaneous sensors.

03

Conditions studied

  • Diabetes Type 2
04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Type 2 diabetes
  • (BMI) > 20 kg/m2
  • \< 58 mmol/mol

Exclusion criteria

Exclusion Criteria:

  • Current pharmacological therapy for diabetes (of any kind)
  • Pregnancy or lactation
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

05

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Double (Participant, Outcomes assessor)
Enrollment
30 participants (actual)

Study arms

  • Experimental
    Senatore Cappelli pasta

    Other: Pasta manufactured with traditional wheat varieties (Senatore Cappelli, Korasan)

  • Experimental
    Korasan pasta

    Other: Pasta manufactured with traditional wheat varieties (Senatore Cappelli, Korasan)

  • Active comparator
    Claudio pasta

    Other: Pasta manufactured with current wheat varieties (Claudio)

Interventions

  • OtherPasta manufactured with traditional wheat varieties (Senatore Cappelli, Korasan)

    A single meal composed of a portion of pasta (with standardized dressing) manufactured with different wheat varieties

  • OtherPasta manufactured with current wheat varieties (Claudio)

    A single meal composed of a portion of pasta (with standardized dressing) manufactured with different wheat varieties

06

What researchers measure

Primary outcomes

  1. 60-min glucose

    Glucose (interstitial monitoring) 60 min after beginning of meal

    Time frame: 60 minutes

Secondary outcomes

  1. 30-min glucose

    Glucose (interstitial monitoring) 30 min after beginning of meal

    Time frame: 30 minutes

  2. 90-min glucose

    Glucose (interstitial monitoring) 90 min after beginning of meal

    Time frame: 90 minutes

  3. 120-min glucose

    Glucose (interstitial monitoring) 120 min after beginning of meal

    Time frame: 120 minutes

  4. 150-min glucose

    Glucose (interstitial monitoring) 150 min after beginning of meal

    Time frame: 150 minutes

  5. 180-min glucose

    Glucose (interstitial monitoring) 180 min after beginning of meal

    Time frame: 180 minutes

  6. Area Under the Curve (AUC) glucose 30 min

    Area under glucose (interstitial monitoring) curve 30 min after beginning of meal

    Time frame: 30 minutes

  7. AUC glucose 60 min

    Area under glucose (interstitial monitoring) curve 60 min after beginning of meal

    Time frame: 60 minutes

  8. AUC glucose 90 min

    Area under glucose (interstitial monitoring) curve 90 min after beginning of meal

    Time frame: 90 minutes

  9. AUC glucose 120 min

    Area under glucose (interstitial monitoring) curve 120 min after beginning of meal

    Time frame: 120 minutes

  10. AUC glucose 180 min

    Area under glucose (interstitial monitoring) curve 180 min after beginning of meal

    Time frame: 180 minutes

07

Study locations

1 site
  • Diabetologia AOU Careggi
    Florence, 50134, Italy
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2021 to primary completion in Jan 2024, 26 months.

Of 2,078 non-industry interventional studies with no phase under Diabetes Mellitus, Type 2, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 40. This study's 26 months is above that.

Counting every sponsor, half of 2,255 studies reached it within 21 months; a quarter within 10 and three quarters within 39.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 27, 2026: primary completion Aug 2022 → Jan 2024 and completion Sep 2022 → Mar 2024.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Nov 23, 2021
First posted
Dec 3, 2021
StartActual
Nov 20, 2021
Primary completionActual
Jan 30, 2024was Aug 2022
CompletionActual
Mar 30, 2024was Sep 2022
Last update
Oct 27, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Status unknown→Completed
changed Oct 27, 2026
Sites
1 site added, 1 site removed
Show site
  • Diabetologia AOU Careggi · Florence, Italy
Show 1 removed
  • Diabetologia AOU Careggi · Firenze, Italy
Oct 27, 2026
Primary completion
Aug 31, 2022→Jan 30, 2024 (actual)
Oct 27, 2026
Study completion
Sep 30, 2022→Mar 30, 2024 (actual)
Oct 27, 2026
Show all 1 update
  1. Oct 27, 2026
    Status unknown→Completed
    1 site added, 1 site removed
    Show site
    • Diabetologia AOU Careggi · Florence, Italy
    Show 1 removed
    • Diabetologia AOU Careggi · Firenze, Italy
    Primary completion Aug 31, 2022→Jan 30, 2024 (now actual)
    Study completion Sep 30, 2022→Mar 30, 2024 (now actual)
    + 3 other changes: verification date, contact details and index terms

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT05143827
Lead sponsor
Azienda Ospedaliero-Universitaria Careggi
Responsible party
Edoardo Mannucci (Director, Diabetology unit, Azienda Ospedaliero-Universitaria Careggi) — Principal investigator
First posted
Dec 3, 2021
Start date
Nov 20, 2021
Primary completion
Jan 30, 2024
Completion
Mar 30, 2024
Last update
Oct 27, 2026

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion